Eli Lilly and Company $LLY Shares Bought by Capital Advisors Inc. OK

Key Points

• Capital Advisors Inc. OK increased its holdings in Eli Lilly by 6.8% during Q2, owning 6,747 shares worth approximately $5.26 million.
• Eli Lilly's quarterly earnings beat expectations with $6.31 earnings per share, against a consensus estimate of $5.59, contributing to a 37.6% year-over-year revenue increase.
• Institutional investors own 82.53% of Eli Lilly's stock, indicating strong institutional interest in the company.

Capital Advisors Inc. OK grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,747 shares of the company's stock after acquiring an additional 429 shares during the quarter. Capital Advisors Inc. OK's holdings in Eli Lilly and Company were worth $5,260,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of LLY. Iowa State Bank lifted its holdings in Eli Lilly and Company by 0.6% in the second quarter. Iowa State Bank now owns 5,587 shares of the company's stock worth $4,355,000 after purchasing an additional 35 shares during the period. Relyea Zuckerberg Hanson LLC lifted its holdings in Eli Lilly and Company by 23.9% in the 2nd quarter. Relyea Zuckerberg Hanson LLC now owns 3,898 shares of the company's stock valued at $3,039,000 after acquiring an additional 752 shares during the last quarter. Belpointe Asset Management LLC lifted its stake in Eli Lilly and Company by 21.0% during the second quarter. Belpointe Asset Management LLC now owns 5,671 shares of the company's stock valued at $4,422,000 after buying an additional 986 shares in the last quarter. Gratus Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 5.4% during the second quarter. Gratus Wealth Advisors LLC now owns 1,737 shares of the company's stock valued at $1,354,000 after buying an additional 89 shares in the last quarter. Finally, Valley National Advisers Inc. lifted its stake in Eli Lilly and Company by 5.4% during the second quarter. Valley National Advisers Inc. now owns 4,835 shares of the company's stock valued at $3,767,000 after buying an additional 246 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 2.5%

NYSE:LLY opened at $840.46 on Monday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market capitalization of $795.46 billion, a PE ratio of 54.93, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The business's 50-day simple moving average is $734.60 and its 200-day simple moving average is $765.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the business posted $3.92 EPS. Eli Lilly and Company's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research reports. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. UBS Group reduced their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. Cantor Fitzgerald dropped their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. Finally, Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $938.94.

Insider Transactions at Eli Lilly and Company

In other news, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jamere Jackson bought 200 shares of the business's stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.